Management of anemia associated with myelodysplastic syndrome
- 1 April 2005
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 42 (2), S10-S13
- https://doi.org/10.1053/j.seminhematol.2005.01.002
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- The WHO classification of MDS does make a differenceBlood, 2004
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of lifeBritish Journal of Haematology, 2003
- Recent progress in the treatment of myelodysplastic syndrome in adult patientsCurrent Opinion in Oncology, 2003
- Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromesZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromesBritish Journal of Haematology, 1998
- Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive modelBritish Journal of Haematology, 1997
- The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overloadBritish Journal of Haematology, 1996
- Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studiesBritish Journal of Haematology, 1995
- MANAGEMENT OF MYELODYSPLASTIC SYNDROMESBritish Journal of Haematology, 1993
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982